Markets
United States Antimony Stock Plunges 8% After Monday's Results-Call Transcript Filing
The metals company's third-quarter revenue rose 16.5%, but it recorded a $9.5 million net loss.
SEC Filings
Cisco opposed the proposal, saying its existing independent assessments already examine sensitive customers and potential product misuse.
Markets
The Canadian drone maker's proposed Philippine joint venture still requires agreement on ownership, technology licensing and operations.
Markets
The database company plans automatic synchronization for live-data analysis and continued support for existing Firebolt customers.
Madryn's restrictions extend 30 days beyond the final prospectus, while a separate agreement binds Avinash Amin for 90 days.
The satellite builder expects to file within five calendar days of its original deadline as it restates earlier accounts.
The investor reported no recent stock trades, while Rumble's CEO retained 80% voting control.
Jorey retained a 2.7% stake as the treatment-system company sought fresh capital and relief from loan requirements.
PEMGARDA sales rose 18%, but its emergency authorization is due to end in mid-2027.
New stories throughout the week, including weekends, when there is news to report. Free email wraps: 7:30 AM, 11:30 AM and 4:30 PM on trading days, plus Sundays at 5 PM (Eastern Time). No new stories, no email.
Corrections including a satellite write-down are expected to add approximately $4.1 million to its previously reported first-half loss.
The defense supplier's factory deals include export royalties and purchase commitments, while its order backlog stands at $33 billion.
The royalty-funded drug developer also faces a leadership change, with its chief executive planning to retire by February 2027.
Richard McPhail backed continued reinvestment as analysts questioned acquisition margins and earnings growth ahead of his Monday succession.
A $20 million Takeda milestone payment preceded the authorization, but management can choose to purchase no shares.
Warrant shares made up much of the reported holding as the DNA-medicine developer prepares to launch its newly approved treatment.
Revenue grew across every segment and region, while management added $30 million in investment spending.
Opera raised its full-year revenue outlook and plans to remove recurring depositary fees through a switch to ordinary shares.
North American subscribers fell even as fourth-quarter adjusted earnings improved, and the company plans to expand beyond pay TV.
Viatris expects Pacira to contribute $90 million to $100 million in revenue for the remainder of 2026.
The rally added $1 billion in market value, while Aecom expects construction projects to consume about $500 million in fiscal 2027.
Drug sales rose 26% from the second quarter, but non-cash valuation losses left Omeros with a reported loss.